Predicting Outcomes in Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Early Phase Immunotherapy Trials

OBJECTIVES: Immunotherapy (IO) has altered the non-small cell lung cancer (NSCLC) therapeutic landscape. However, the majority of patients do not respond to immune-checkpoint blockade, and subsequently either receive further chemotherapy or are referred for clinical trials. Here we examined the outc...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Lung Cancer
Autors principals: Maymani, Hossein, Hess, Kenneth, Groisberg, Roman, Hong, David S, Naing, Aung, Piha-Paul, Sarina, Janku, Filip, Fu, Siqing, Tsimberidou, Apostolia M., Pant, Shubham, Karp, Daniel, Liu, Shuang, Sun, Ming, Heymach, John, Simon, George, Meric-Bernstam, Funda, Subbiah, Vivek
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204221/
https://ncbi.nlm.nih.gov/pubmed/29748008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2018.03.020
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars